Serum clusterin as a promising diagnostic and prognostic marker for hepatocellular carcinoma after locoregional treatment

• Published in: The Egyptian journal of immunology Vol. 29; no. 2; p. 26
• Main Authors: Rasmy, Hany S, Mohammed, Hatem A, Mohammed, Eslam S, Ahmed, Aml S M, Isaac, Amira
• Format: Journal Article
• Language: English
• Published: Egypt 01.04.2022
• Subjects: alpha-Fetoproteins; Biomarkers, Tumor; Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - therapy; Clusterin; Humans; Liver Cirrhosis; Liver Neoplasms - diagnosis; Liver Neoplasms - therapy; Prognosis
• ISSN: 1110-4902
• DOI: 10.55133/eji.290204

Hepatocellular carcinoma (HCC) is one of the most common aggressive tumors, with a rising prevalence in Egypt. Clusterin is a secretory heterodimeric glycoprotein linked to cancer development and progression. This study was conducted to evaluate the diagnostic and prognostic role of serum clusterin as a possible biomarker of HCC and correlate its level with the mRECIST scoring system. This study included 45 patients with liver cirrhosis and HCC eligible for locoregional treatment and 20 patients with liver cirrhosis without HCC as controls. All patients underwent standard laboratory tests and abdominal ultrasound. For HCC patients, a triphasic CT scan, alpha-fetoprotein (AFP), and clusterin levels were measured at baseline and one month after intervention. HCC patients had a substantially higher baseline clusterin level than cirrhotic patients (122.291 ± 61.898 vs. 74.015 ± 41.571, P = 0.002). Five patients in the HCC group were not eligible for intervention because they had evidence of portal vein invasion. At one month follow-up after HCC treatment, serum clusterin levels declined significantly from baseline (from 122.291 ± 61.898 to 81.125 ± 62.321, P = < 0.001). According to the mRECIST scoring, baseline clusterin levels were significantly higher among patients with progressive disease than those with partial response than those with complete response (180.722 ± 55.908, 161.310 ± 56.339, 84.810± 41.389, respectively, overall P = < 0.001). Clusterin was a useful marker in detecting HCC with 73.33% sensitivity and 75% specificity at a cutoff of ≥ 86.6 mg/L, and it also had 95.24% sensitivity and 77.78% specificity in detecting tumor progression at a cutoff of ≥ 146.6 mg/L, according to the mRECIST scoring system. In conclusion, clusterin may be a helpful diagnostic and prognostic marker for HCC after locoregional treatment, as its baseline level is useful in predicting response and progression of HCC in correlation with the mRECIST scoring system.